Buchumschlag

Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

Background: Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative expe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Metzelder, Stephan (VerfasserIn) , Dreger, Peter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: November 2017
In: European journal of cancer
Year: 2017, Jahrgang: 86, Pages: 233-239
ISSN:1879-0852
DOI:10.1016/j.ejca.2017.09.016
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1016/j.ejca.2017.09.016
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804917312972
Volltext
Verfasserangaben:S.K. Metzelder, T. Schroeder, M. Lübbert, M. Ditschkowski, K. Götze, S. Scholl, R.G. Meyer, P. Dreger, N. Basara, M.F. Fey, H.R. Salih, A. Finck, T. Pabst, A. Giagounidis, G. Kobbe, E. Wollmer, J. Finke, A. Neubauer, A. Burchert
Beschreibung
Zusammenfassung:Background: Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available. Methods: We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD-positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy. Findings: With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years. Interpretation: Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT.
Beschreibung:Gesehen am 29.10.2018
Beschreibung:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2017.09.016

Ähnliche Einträge